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STUMBLING OVER TRIPS: THE INTERNATIONAL
INTELLECTUAL PROPERTY WAIVER PETITION
AND THE U.S. EXECUTIVE
JordanParadise& ChristinaConroy
This article examines the relationship among intellectual property (IP)
law protections; United States (U.S.) and international law and policy; and
the actualization of diagnostics, drugs, and vaccines in the time of the
COVID-19 coronavirus. Two key international treaties that relate to IP
law -The Trade-Related Aspects of Intellectual Property Rights (TRIPS)
Agreement and the Doha Declaration on the TRIPS Agreement and Public
Health (Doha Declaration) - establish international norms for the
protection of IP. Core aspects of each of these treaties are described along
with the role of the World Trade Organization (WTO) and concepts of
compulsory licensing. As a result of COVID-19, there have been recent
calls for an international IP waiver to TRIPS to address disparities in
access to health and medical products during the pandemic. The article
traces the timeline of the waiver petition, beginning with its initiation by
South Africa and India in October 2020, through the emergence of the
omicron variant in November 2021. The waiver continues to generate
significant controversy, with staunch opposition from the European Union
and several other developed countries, including early opposition from the
U.S. The Biden Administration has signaled support for the waiver,
although the extent of that support has not been fully demarcated. Several
alternative models have arisen, which are also discussed in connection
with the general lack of progress of the WTO to implement any such
waiver as of early 2022.
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I. INTRODUCTION

As the COVID-19 pandemic has unfolded, widespread acts of vaccine
and patent nationalism have fostered significant vaccine inequity. The
World Health Organization (WHO) reports that as of July 2021, just ten
countries account for seventy-five percent of vaccine administrations, with
only one percent of low-income country populations having received a
single dose of the vaccine. 1 In the United States (U.S.), drug and vaccine
incentives are driven largely through intellectual property protections
granted by the Patent and Trademark Office and product exclusivity
periods issued by the Food and Drug Administration. 2 Longstanding
alternative, non-exclusionary models supporting access to medical
innovations include compulsory licensing;3 exercise of governmental
march-in rights;4 patent pooling; open source collaborations and
platforms; and voluntary industry pledges not to enforce particular patents
or to provide access to materials, methods, or products.5
In the face of such extreme vaccine inequity, another access model has
emerged: a petition for the implementation of a waiver to the international
World Trade Organization (WTO) Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS). This article examines the history
and development of the petition for waiver of intellectual property (IP)
protections, the changing position of the U.S. Executive branch, and
proposed alternative models for access and distribution during the
pandemic. Part II identifies international entities, treaties, and processes
related to IP rights and explores the development of the current
1. Bruce Baschuk, WTO HolidayFrom Vaccine Equity TalksDrawsCallsforAction,
BLOOMBERG NEWs, July 27, 2021, https://www.bloomberg.com/news/articles/2021-0726/wto-s-holiday-from-vaccine-equity-talks-draws-calls-foraction?utmcampaign=pharmalittle&utmmedium=email&_hsmi=143777081 &_hsenc=
p2ANqtz9tlelr6qvvPgAJrvE6gmzfMgFZIQYTgaVnvx3tUoOm4rbe5BB4dEM4rljph8oaDVJG5b
54HDbW1 XFQhaj8CFPwaLPpVA&utm_content=143777081 &utm_source=hs_email.

2. See Jordan Paradise, Information Opacity in BiopharmaceuticalInnovation
Through the Lens of COVD-19, 47 AM. J. L. & MED. 157 (2021) (discussing the
intertwining roles of each agency).
3.
See, e.g., Sapna Kumar, CompulsoryLicensing ofPatentsDuring Pandemics,
54 CONN. L. REV (forthcoming).
4.
Jordan Paradise, COVID-IP: Staring Down the Bayh-Dole Act with 2020
Vision, 7 J. L. & THE BIOsCIENCES 1 (2020).

5.

See Jorge Contrearas et al., PledgingIntellectualPropertyfor COVID-19, 38

NAT'L BIOTECHNOLOGY 1 146 (2020).
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international IP paradigm structured through TRIPS and the Doha
Declaration. Part III traces the history of the IP waiver petition as a
response to the COVID-19 pandemic, including support and opposition,
scope of the waiver, and the relationship to the existing IP paradigms. Part
IV turns to the evolution of the position of the U.S. regarding the waiver,
comparing the Trump Administration and the Biden Administration's
statements and representations. Part V examines alternative models for
access and distribution and the explores the feasibility of each approach in
the face of the pandemic. The article then concludes, acknowledging
international uncertainty and a lack of resolution regarding the waiver.
II. PANDEMIC ACRONYMS AND AUTHORITIES: WHO, WTO, TRIPS, AND

DOHA
At the global scale, the WHO is the world's lead actor in pandemic
response efforts. The WHO declared the novel coronavirus outbreak a
pandemic in March 2020 following several cases of the disease reported
outside of the outbreak epicenter. 6 The WHO initiated a three-part Access

to COVID-19 Tools (ACT) initiative in April 2020,7 which includes the
COVID-19 Vaccines Global Access (COVAX) collaboration to ensure
global access to COVID-19 vaccines.' Along with the WHO, the Coalition
for Epidemic Preparedness Innovations and the Gavi Vaccine Alliance
lead the COVAX collaboration.9 By August 2020, 172 countries were
engaged in the Global Access Facility within COVAX responsible for the
distribution of vaccines. 1 Initially the U.S. (under President Trump) and a
small number of other countries refused to join the COVAX effort."

6. Listings of WHO's Response to COVID-19, WORLD HEALTH ORGANIZATION,
Jan. 29, 2021, https://www.who.int/news/item/29-06-2020-covidtimeline.
7.
World Health Organization, Access to COVID-19 Tools (ACT) Accelerator,
Apr. 24, 2020, https://www.who.int/initiatives/act-accelerator.
8.
172 Countries and Multiple Candidate Vaccines Engaged in COVID-19
Vaccine Global Access Facility, WORLD HEALTH ORGANIZATION, Aug. 24, 2020,
https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-candidatevaccines-engaged-in-covid-19-vaccine-global-access-facility.

9.
10.

Id.
Id.

11.

Emily Rauhala & Yasmeen Abutaleb, US. Says It Won't Join WHO-Linked

Effort to Develop, Distribute Coronavirus Vaccine,

WASHINGTON POST,

https://www.washinptonpost.com/world/coronavirus-vaccine-

trump/2020/09/01/b44b42be-e965-1lea-bf44-0d31c85838a5

storv.html.

Sept. 1, 2020,
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President Trump also withdrew the U.S. from the WHO in July 2020
despite vocal opposition from public health experts.12
Within weeks of taking office, President Biden reversed the course of
the Trump administration and joined the international pandemic response
and vaccine development efforts.13 President Biden has since pledged the
distribution of 25 million doses of COVID vaccines from the United States
stockpile to countries around the world.1 4 Roughly seventy-five percent
of those doses would be channeled through COVAX, the international
effort to disseminate medical products during the pandemic.15 The U.S.
has earmarked $2 billion to Gavi to provide vaccines for ninety-two lowand middle-income economies. 16
Alongside the international collaborative efforts of the WHO and other
entities are legal frameworks to adjust the status of IP protections to
respond to crises. The WTO, another key actor, is responsible for the
implementation of international agreements regarding IP protections
during a global pandemic. Complex procedural and logistic challenges
exist at the crossroads of IP protections and the need for rapid, widespread
production and distribution of vaccines, and pharmaceutical and medical
device products. The WTO, via the Agreement on the Trade-Related
Aspects of Intellectual Property Rights (TRIPS) and the Doha Declaration,
recognizes that public health crises will sometimes require special
attention or compel different obligations on WTO member states.17
TRIPS is an agreement, binding on WTO member countries, that
provides minimum standards, not uniform laws, for intellectual
property rights.

12. Janice Hopkins Tanne, COVID-19: U.S. Will Not Join WHO in Developing
Vaccine, 370 BMJ m3396 (2020).
13.
The White House, Fact Sheet: President Biden to Take Action on Global
Health through Support of COVAX and Callingfor Health Security Financing, Feb. 18,
2021,
https://www.whitehouse.gov/briefmg-room/statements-releases/2021/02/18/factsheet-president-biden-to-take-action-on-global-health-through-support- of-covax-andcalling-for-health-security-financing/.
14.
Stephen Wertheim, America Pursues Vaccine Internationalism - but What
Kind?, THE NATION, June 7, 2021, https://www.thenation.com/article/politics/vaccinecovax-intemationalism/.

15.

Id.

16.
17.

The White House, supra note 13.
World Trade Organization, Doha Declaration on the TRIPS Agreement and

Public Health, WT/MIN(01)(DEC/2, 41 I.L.M. 755 (2001).

Michigan State InternationalLaw Review

254

[Vol. 30.2

The WHO and WTO Secretariat jointly recognize that patent
protections are important and influential in the pharmaceutical industry
and medical equipment industry given high research and development
costs, length of clinical trials, and regulatory review and approval.1
Vaccine research is fueled by the protections and financial incentives
afforded by patents due to the characteristics of vaccines, as complex
biological rather than relatively-simple chemical products, which makes
their development and manufacturing extremely costly. Compared to
pharmaceutical companies, there are relatively fewer vaccine
manufacturers globally because vaccines are sensitive biological products
that require strict control for safety, quality, procurement, and distribution.
Manufacturers must possess sophisticated technical knowledge to produce
vaccines; often, such knowledge is not readily available or accessible
because of patents, trade secrets, or other IP protections.19 Patents, trade
secrets, and technological knowledge assigned to large companies with
licensing schemes have created a web of intellectual property that is not
easily navigated.20 Notably, thirteen European Union (E.U.) member
states possess over sixty percent of the world's major facilities for vaccine
production and ninety percent of global vaccine production.2 1
Since the inception of TRIPS, and the subsequent creation of the Doha
Declaration resulting in Article 31bis of TRIPS, several international
public health emergencies have provided the need for utilization of the IP
adaptation mechanisms. One prime example is the AIDS crisis. In the
late 1990s, TRIPS flexibilities and individual countries' compulsory
licensing frameworks became a method to deal with HIV/AIDS epidemics
and the high cost of Gilead's approved AIDS drug.22 Many developing
countries were concerned that TRIPS was restricting access to HIV/AIDS
drugs, and important tuberculosis and malaria drugs, which eventually led
18.
World Health Organization & World Trade Organization Secretariat, WTO
Agreements and Public Health, at 92 (2002),
https://www.wto.org/english/rese/bookspe/who wto e.pdf.

19.
20.
Vaccine

Id. at 97.
Mario Gaviria & Burcu Kilic, A Network Analysis of COVID-19 mRNA
Patents,

39

NATURE

BIOTECH.

546,

546

(2021),

https://www.nature.com/articles/s41587-021-00912-9.
21.

Kayvan Bozorgmehr et al., Free Licensing of Vaccines to End the COVID-19

Crisis, U. S. NAT. LIR. MED., 1261, 1262, Mar. 18, 2021,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972308/.
22.

JacquiWise,AccesstoAlDSMedicinesStumblesonTradeRules, BULL. WTO

342, 342 (May 2006), https://apps.who.int/iris/handle/10665/269649.
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to the Doha Declaration in 2001.23 The Doha Declaration set out a
compulsory licensing scheme within TRIPS, in a new Article 31bis.24 A
compulsory license allows a country or authorized third party to use a
patented invention without the patent owner's permission, in exchange for
a government-determined royalty.2 5 TRIPS outlines the requirements for
countries seeking to grant a compulsory license. Members must evaluate
patents on individual bases to determine whether a license is appropriate,
and if so, the proper amount of royalty. To procure a compulsory license,
the party seeking licensure must attempt and fail to get a voluntary license
from the patent owner first via "prior negotiations," a process that is not
well-defined. Waiver of the prior negotiation requirement is acceptable in
cases of: (1) national emergency, (2) circumstances of extreme urgency,
or (3) public non-commercial use, so long as the patent owner is notified
as soon as is practicable.
Compulsory licensing via TRIPS is currently disfavored among many
countries, and very few countries issue them. Countries who are opposed
to compulsory licensing often pressure other countries to not issue them.
Furthermore, the TRIPS requirements are procedurally difficult for many
countries to follow, making compulsory licenses impractical. Between
1995-2011, twenty-four TRIPS-Doha attempts to procure compulsory
licenses for pharmaceutical products were issued.26 The highest period of
activity in compulsory licensing occurred right after the Doha Declaration
was passed.27 The diseases dealt with included HIV/AIDS, anthrax,

23.
24.

Id.
WTO Analytical Index, TRIPS Agreement - Article 31bis (Practice), Mar.

2021, https://www.wto.org/englishl/rese/publications_e/ail 7_e/tripsart31_bisoth.pdf.
Article 31bis provides, in part: "The obligations of an exporting Member under Article
31(f) shall not apply with respect to the grant by it of a compulsory license to the extent
necessary for the purposes of production of a pharmaceutical product(s) and its export to
an eligible importing Member(s) in accordance with the terms set out in paragraph 2 of the
Annex to this Agreement." Id.
25.
Sapna Kumar, supra note 3, at 6.
26.
Reed Beall & Randall Kuhn, Trends in Compulsory Licensing of
PharmaceuticalsSince the Doha Declaration:A DatabaseAnalysis, 9(1) PLOS MED. 1
(2012), https://journals.plos.org/plosmedicine/article?id=1 0.1371/journal.pmed. 100 1154.

27.

Id, at 1.
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pandemic
influenza,
cancer,
cardiovascular
disease,
and
28
disease.
noncommunicable
The first country to procure a framework for compulsory licensing
amidst COVID was Brazil.29 Subsequently, Israel, Hungary, and Russia
issued compulsory licenses for COVID therapeutics, while Chile,
Colombia, and Indonesia made proposals for new laws increasing barriers
to compulsory licenses. 30 In early 2021, Biolyse Pharma Corp., a company
with the manufacturing capacity to make 20 million vaccine doses
annually, threatened to apply for a compulsory license for the Johnson
28.
Id, at 4. (following the first decade of the 2000s, Thailand dominated the
compulsory license scene. Thailand used licenses for twenty drugs, including those for
HIV/AIDS, cancer, and cardiovascular disease. Brazil followed and issued a compulsory
license for antiretroviral drug (ARV) Nelfinavir, and then another drug in 2007. Rwanda
used the provisions of the Doha Declaration to request manufacturing of a Canadian drug,
and Canada became the first country to issue a compulsory license for exporting a generic
drug to a third country. Following the Rwanda-Canada success, several developed
countries used compulsory licensing to provide ARVs to poorer countries and to halt
anticompetitive actions. In 2006, the WTO made a landmark decision to allow a generic
copy made under a compulsory license to be exported to developing countries. Zimbabwe
declared its 2002 AIDS epidemic a period of emergency and authorized the government to
override patents to permit the local production or import of ARVs. In 2003, Malaysia
allowed the import of certain medicines from India. In 2004, Mozambique and Zambia
issued compulsory licenses for local production of ARVs, while Indonesia authorized
government use of patents to enable local production of two drugs. Some LDCs, as of 2006,
allowed the import of generics and refused to issue patents, which is proper under the
TRIPS exemption for LDCs Both South Africa and Kenya obtained voluntary licenses for
local ARVs, though with a great deal of pressure and difficulty. A great number of solutions
sought in the early 2000s to deal with HIV/AID S epidemics related to compulsory licensing
and the import and export of generics, refusal to patent certain drugs in LDCs, and some
rare instances of voluntary licensing There was no global instance of a waiver of IP
requirements under TRIPS or broadening of the exemption from TRIPS requirements for
LDCs); See also Charitini Stavropoulou & Tommaso Valletti, Compulsory Licensing and
Access to Drugs, 16 EUR. J. HEALTH EcON. 84 (2015).
29.
Britain Eakin, iP Waiver Talks Hinge on Use of Big Pharma'sTrade Secrets,
LAw360, May 25, 2021, https://www.law360.com/lifesciences/articles/1388176/ipwaiver-talks-hinge-on-use-of-big-pharma-s-trade-secrets?rdpk=10d3bl b5-5f83-4189-

938adf7f5d9ca046&utm_source-newsletter&utm_medium=email&utm

campaignlifescienc

es.
30.

Tiffany Hu, US Ranks 2nd in GlobalPatentProtection
for 3rd Year, Law360,

Mar. 25, 2021, https://www.law360.com/lifesciences/articles/1368344/us-ranks-2nd-inglobal-patent-protection-for-3rd-year?nlpk=10d3b 1b5-5f83-4189-938adf7f5d9ca046&utm_source-newsletter&utmmedium=email&utm campaign=lifescienc

es.
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Johnson vaccine through the Canadian Access to Medicines Regime, after
failing to receive a voluntary license upon its first request.31 The World
Intellectual Property Organization has published a COVID IP Policy
Tracker to keep up with the function of member state intellectual property
offices and supporting regulatory agencies amidst COVID-19.32
III. THE HISTORY OF THE IP WAIVER PETITION

South Africa and India led the global effort to propose a waiver of
intellectual property rights when they jointly proposed an exemption to
specific articles of the TRIPS amidst the COVID-19 pandemic. On
October 2, 2020, South Africa and India proposed that the WTO waive or
adjust intellectual property requirements on copyrights, industrial designs,
patents, protection of undisclosed information, and compulsory licenses."
The proposal cites more than one million COVID-related deaths and more
than three hundred million confirmed global cases of COVID as an
extreme and unique circumstance. South Africa and India noted that the
WTO member countries, not only least-developed countries, were
struggling to access COVID-19 treatments in a timely fashion and in the
volume necessary to deal with the ongoing and growing pandemic.
The South Africa-India proposal goes further in saying that the shortage
of treatments has the power to exacerbate both the short and long-term
negative consequences of the pandemic.34 The proposal urges the WTO to
waive TRIPS requirements in the COVID context until there is widespread
vaccination on the global scale and the majority of the world's population
has developed immunity.3 5 The waiver would be renewed each year until
the General Council of the WTO determined that it was no longer
31.
Mari Serebrov, CanadianCompany to J&J: License, or Else...., BJowoRLD,
Mar.
15, 2021, https://www.bioworld.com/articles/504737-canadian-company-to-jjlicense-or-else?v-preview.
32.
World Intellectual Property Organization, COVID-19 IP Policy Tracker,
https://www.wipo.int/covidl 9-policy-tracker/#/covidl 9-policy-tracker/ipo-operations

(visited Jan. 18, 2022).
33.
Communication to the TRIPS Council of the WTO by South Africa and India,
Waiver from CertainProvisions of the TRIPS Agreementfor the Prevention, Containment

and Treatment of COVID-19, WTO Doc. IP/C/W/669 (Oct. 2, 2020) (noting that the
respective provisions of TRIPS are Section 1, Section 4, Section 5, Section 7, and Article

31 bis).
34.
35.

Id, at1.
Id.
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necessary. There is no further clarification in the original proposal
regarding when either of those events are triggered, how they will be
measured, and what mechanisms will be used to effectuate them. South
Africa, India, and their supporters are pushing for the WTO to waive a
number of intellectual property requirements that are binding via TRIPS.
In addition, the proposal that Article 31bis on compulsory licenses would
greatly hinder countries lacking sophisticated and sufficient
manufacturing capacity in being able to access COVID vaccines and
treatments under the regular TRIPS structure, and that its provisions
should thus also be waived.
Immediately following the October 2020 proposal by India and South
Africa, the WTO members met to discuss the waiver and other related
proposals.3 6 WTO member states discussed the possibility of extending the
grace period offered to less-developed countries in implementing the
TRIPS agreement after Chad, on behalf of the LDC WTO member group,
made such a proposal to the TRIPS Council.3 7 Members also discussed
competitiveness issues for micro, small, and medium enterprises
(MSMEs) through the protection of IP rights. The TRIPS Council
suspended the proposal and planned to reconvene in December 2020,
following the first WTO conference on the South Africa-India waiver
proposal. In general, member states expressed support for some version of
an IP waiver via TRIPS pursuant to the proposal.
The December 2020 meeting of the WTO members included further
discussion of the South Africa-India proposal.38 The TRIPS Council did
not rule on the waiver request prior to the meeting and extended their 90day period to do so. 39 The WTO members met subsequently in March
2021.*0 By the March 2021 meeting, the proposal had been co-sponsored
36.
World Trade Organization, Press Release, Members Discuss Intellectual
PropertyResponse to the COVID-19 Pandemic, October 20, 2020,

https://www.wto.org/english/news_e/news20_e/trip_20oct20_e.htm.
37.
Communication to the TRIPS Council of the WTO by Chad on behalf of the
LDC Group, Extension of the Transition Period under TRIPS Article 66.1 for Least
Developed Country Members, WTO Doc. IP/C/W/668 (Oct. 1, 2020).
38.
World Trade Organization, Members to Continue Discussion on Proposalfor
Temporary
IP
Waiver
in Response
to
COVID-19,
May
10,
2020,

https://www.wto.org/english/newse/news20_e/trip_10dec20_e.htm.
39. Id.
40.
World Trade Organization, Members Discuss TRIPS Waiver, LDC Transition
Period and Green Tech Role for Small Business, Mar. 11, 2021,
https://www.wto.org/english/news_e/news2l _e/trip_11mar21_e.htm.

Stumbling Over TRIPS

2022]

259

by nine countries, the African Group, and the LDCs group.41 On May 25,
2021, several WTO member states, the African Group, and the LDCs
group submitted a revised version of the original South Africa-India
proposal.42 As of May 26, 2021, Jordan requested to officially join in its
support of the waiver, increasing the number of signed supporters to
thirteen countries and two WTO groups.43 The TRIPS Council had not yet
ruled on the proposals, and no decision was made regarding extension of
the LDC transition period, which was set to expire on July 1, 2021.4 The
WTO members met again in April 2021 and held that the General Council
had to make a decision on the waiver proposal by May 5th or 6th, 2021.4
Note that the holding of the WTO members was merely a decision to
schedule a discussion, and that there is no formal recourse in the event that
the meeting fails to happen. Sixty WTO member countries supported the
waiver proposal.46 There was no decision by the TRIPS Council on the
proposal at that time.47 Despite the meetings of the WTO members

41. Id. Bolivia, Egypt, Eswatini, Kenya, Mongolia, Mozambique, Pakistan,
Venezuela, and Zimbabwe co-sponsored the South Africa-India proposal as of March
2021. Council for Trade-Related Aspects of Intellectual Prop. Rights, Waiverfrom Certain
Provisions of the TRIPS Agreement for the Prevention, Containment and Treatment of
COVID-19: Communicationfrom the African Group, the PlurinationalState of Bolivia,
Egypt, Eswatini, Fri, India, Indonesia, Kenya, The LDC Group, Maldives, Mozambique,
Mongolia, Namibia, Pakistan, South Africa, Vanuatu, the Bolivarian Republic of
Venezuela and Zimbabwe, WTO Doc. IP/C/W/669/Rev.1 (May 25, 2021) [hereinafter

WTO Waiver, May 25, 2021].
42.
Communication to the TRIPS Council of the WTO by South Africa and India,
Waiver from CertainProvisions ofthe TRIPS Agreementfor the Prevention, Containment
and Treatment of COVID-1 9, supranote 33.
43.
Addendum, Waiver from CertainProvisions of the TRIPS Agreement for the
Prevention, Containment, and Treatment of COVD-19: Communicationfrom India and
South Africa, (visited January 3, 2022),
https://docs.wto.org/dol2fe/Pages/FESearch/FE_S_S009-

DP.aspx?language=E&CatalogueIdList=274473,274404,274395,274268,274269,274271,
274186,273996,273770,273787&CurrentCatalogueldlndex=3&FullTextHash=&HasEngl
ishRecord=True&HasFrenchRecord=True&HasSpanishRecord=True.
44.
Communication to the TRIPS Council of the WTO by Chad on behalf of the
LCD Group, Extension of the Transition Period under TRIPS Article 66.1 for Least
Developed Country Members, supranote 37.
45.
TRIPS Council to Continue to Discuss Temporary IP Waiver, Revised
ProposalExpected in May, WTO, April 30, 2021,
https://www.wto.org/english/news_e/news2le/trip_30apr21 _e.htm.
46. Id.

47.

Id.
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following the South Africa-India proposal, there has not been a decision
on the waiver by the TRIPS Council and the proposal is still pending.
The TRIPS Council met on June 8-9, 2021 to discuss the proposed
waiver and decided to proceed to text-based negotiations regarding the
proposal. 48 The text-based negotiation is to take place via a WTO General
Council meeting.4 9 A draft of the negotiations, which aims to satisfy every
member state in order to reach consensus, will be presented at the
upcoming meeting on July 21-22.5o Negotiations in this format allow
dissenters or opponents to negotiate specific provisions of the proposed
waiver, seek compromises, or make changes to the proposal.51 The EU has
put forth its own alternative proposal to the existing proposal and revision
before the WTO, and despite growing international support, several EU
countries still oppose the waiver.5 2
On June 24, 2021, the TRIPS committee met to discuss the EU's plan
for increasing vaccine access during the pandemic.53 The EU proposal is
an alternative to the proposed waiver by WTO member states.5 4 The
proposal suggests the safeguarding of IP protections and the utilization of
TRIPS flexibilities to increase vaccine access, rather than waiving the
provisions.5 5 The main call of action of the EU's plan is to members,
asking them to "ensure that vaccine and treatment products can cross
borders freely, to avoid disruptions to global supply chains and to not
restrict supplies to COVID-19 Vaccines Global Access, the WTO body
designed to provide vaccines to poorer countries. 5 6 Supporters of the E.U.
plan argue that it will be implemented quickly and will neither require
negotiation of patent rights nor require the length of time attributed to

48. Andrew Green, WTO Council Offers Hope for TRIPS Vaccine Proposal,
DEVEx, June 10, 2021, https://www.devex.com/news/wto-council-offers-hope-for-tripsvaccine-proposal-100125.
49. Id.
50. Id.
51.

Id.

52.

Id.

53. Tiffany Hu, WTO Panel Debates EU's Alternative to IP Waiver Proposal,
LAw360, June 24, 2021, https://www.law360.com/lifesciences/articles/1397412/wtopanel-debates-eu-s-altemative-to-ip-waiver-proposal?nlpk=10d3b1 b5-5f83-4189-938adf7f5d9ca0 46&utm_source=newsletter&utmmedium=email&utmcampaign=lifescienc

es.
54.

Id.

55.

Id.

56.

Id.
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compulsory licensing.57 Some supporters of the TRIPS waiver, like South
Africa and India, opposed the E.U.'s plan, stating that it was an
unnecessary repetition of flexibilities that already exist under TRIPS75
The US, UK, and other members entertained the idea of the E.U.'s plan
but "asked for more clarification." 9
On July 20, 2021, the TRIPS Council again met to consider the
language and scope of the proposed waiver. 60 The members approved a
status report on waiver negotiations to be presented at the July 27-28
meeting of the General Council. 61 At the time of the late-July TRIPS
Council meeting, two divergent opinions generally remained throughout
the members of the WTO regarding whether the waiver should be
implemented. 62 The meeting closed without any resolution on the matter,
despite outcry from public health officials and member countries. 63
At the July 27-28 General Council meeting of the WTO, the chair of
the TRIPS Council reported that the TRIPS Council had engaged in further
discussions of the proposed waiver, as initiated by South Africa and India
and revised and endorsed by several other countries. 64 The TRIPS Council
has also been considering a proposal from the E.U. for a draft General
Council declaration on TRIPS and public health issues despite the
pandemic. 65 The fundamental disagreement between whether there should
be a waiver of intellectual property rights at all and how that waiver should
come to light has caused a delay in coming to a conclusion on the proposed
waiver, especially where the E.U.'s proposal is logically at-odds with the
waiver proposal. 66 The chair suggested that the meetings and negotiations
will likely continue in both formal and informal contexts. 67 The WTO

57.

Id.

58.
59.

Id.
Id.

60.
World Trade Organization, TRIPS CouncilAgrees to Continue Discussionson
JP Response to COVID-19, July 20, 2021,
https://www.wto.org/english/news_e/news2le/trip 20jul21 e.htm.

61.
62.

Id.

63.
64.

Id.
World Trade Organization, Chair Urges Members to Focus on Priorities,

Id.

Outcome for MC12, July 28, 2021,
https://www.wto.org/english/news_e/news2 _e/gc_28jul2 le.htm.

65.

Id.

66.

Id.

67.

Id.
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General Council has not discussed the TRIPS waiver on the official agenda
since July 28, 2021. The WTO General Council reconvened in September
2021, taking no further action on the waiver petition. 68 In November 2021,
as the omicron variant emerged as a virulent and predominant strain of the
virus, President Biden reiterated support for the waiver, yet without
articulating the extent of that support or what form the waiver should be
adopted. 69 A White House statement dated November 26, 2021, provides:
I call on the nations gathering next week for the World Trade
Organization ministerial meeting to meet the U.S. challenge to waive
intellectual property protections for COVID vaccines, so these vaccines
can be manufactured globally. I endorsed this position in April; this
news today reiterates the importance of moving on this quickly. 70

Despite the strong sentiment to the U.S. public, the Biden administration
has been criticized for failing to engage in productive conversation with
countries currently opposing the IP waiver. 71 The same day Biden issued
his statement, the WTO ministerial conference of the General Council was
postponed indefinitely because of the risks posed by the omicron variant.72
Figure 1 depicts key dates and actors involved in the waiver petition
spanning October 2020 through November 2021.

68.

Baschuk, supra note 1.

69.

Walker Bragman, Where Is Biden In the Global War on Omicron?, THE DAILY
POSTER, Dec. 7, 2021, https://www.dailyposter.com/where-is-biden-in-the-global-war-onomicron/.
70.
The White House, Statement from President Joe Biden on the Omicron
COVID-19
Variant, Nov.
26,
2021,
https://www.whitehouse.gov/briefingroom/statements-releases/2021/11/26/statement-by-president-joe-biden-on-the-omicron-

covid-19-variant/
71.
Bragman, supra note 69; Sarah Lazare, Documents Reveal BidenAdmin Not
Fightingfora COVID Vaccine Patent Waiver, DespitePublic Statements, IN THESE TIMES,
Nov.
29,
2021,
https://inthesetimes.com/article/biden-omicron-wto-trips-waiverintellectual-property-patents.
72.
World Trade Organization, General Council Decides to Postpone MC12

Indefinitely, Nov. 26, 2021,
https://www.wto.org/english/news_e/news2l_e/mc12_26nov21 _e.htm.
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Figure 1: Waiver Petition Timeline

Date

Description

10/2/20

South Africa and India propose the waiver of

South Africa and

certain TRIPS provisions for COVID.73

India

WTO member states met to discuss the
proposal and planned to reconvene in
December 2020. Some members suggested
that the TRIPS Council extend the grace

WTO
General
Council,
TRIPS Council

10/15/20;
10/26/20

Actors

period (period of exemption from TRIPS) for
LDCs beyond July 1, 2021.74
11/20/20;
12/3/20

Informal TRIPS Council meetings were held
to discuss the lack of consensus on the
waiver. The Chair referred the TRIPS
Council as the body to hold a meeting and
report to the General Council on the status of
discussions re: the waiver. The TRIPS
Council would have 90 days to report to the
General Council. The 90 days would expire

TRIPS Council
(informal
meetings)

on December 31, 2020. 7
12/10/20

WTO members attended the TRIPS Council

TRIPS Council

meeting. The TRIPS Council planned to
provide its status report to the General

Council on December 16-17, 2020. The
TRIPS Council and General Council
extended the 90-day period for the upcoming

73.
Council for Trade-Related Aspects of Intellectual Prop. Rights, Waiver from
Certain Provisions of the TRIPS Agreement for the Prevention, Containment and

Treatment of COVID-19: Communication from India and South Africa, WTO doc.
IP/C/W/669 (Oct. 2, 2020) [hereinafter WTO Waiver, Oct. 2, 2020].
74. World Trade Organization, Members Discuss Intellectual PropertyResponse

to the COVID-19Pandemic, Oct. 20, 2020,
https://www.wto.org/english/newse/news20 e/trip_20oct20_e.htm.
75.
World Trade Organization, Members to Continue Discussion on Proposal for
Temporary IP Waiver in Response to COVID-19, Dec. 10, 2020,

https://www.wto.org/english/newse/news20_e/trip_10dec20_e.htm.
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Istatus
report and
negotiations. 76

3/10/21;
3/11/21

planned
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to continue

Africa-India proposal. The TRIPS Council

TRIPS Council
Bolivia,
Egypt,

discussed the waiver and the possible
extension of the LDC grace period past July

Eswatini,
Kenya,

1, 2021.

Mongolia,

Nine countries, the African Group, and the
LDCs Group joined to co-sponsor the South

77

Mozambique,
Pakistan,
Venezuela,
Zimbabwe,
the African

Group, and LDCs
Group
4/30/21

The TRIPS Council agreed that the report to

TRIPS Council

the General Council on the waiver will be

submitted by May 5-6, 2021.Co-sponsors of
the waiver proposal announced that they
would submit a revised proposal at the next
General Council meeting. The proposal was
supported by 60 WTO members. 78
5/5/21

U.S. Trade Representative Katherine Tai
announced that the U.S. supports the waiver
in-part. 79

United States

5/25/21

A revised version of the proposal was

WTO
Council,

76.
77.

General

Id.
World Trade Organization, Members Discuss TRIPS Waiver, LDC Transition

Period and Green Tech Role for Small Business, supra note 40.
78.
World Trade Organization, TRIPS Council to Continue to Discuss Temporary
iP Waiver,
Revised
Proposal
Expected
in
May,
Apr.
30,
2021,
https://www.wto.org/english/news_e/news2le/trip_30apr21_e.htm.
79.
Office of the United States Trade Representative, StatementfromAmbassador
Katherine Tai on the Covid-19 Trips Waiver, May 5, 2021, https://ustr.gov/aboutus/policy-offices/press-office/press-releases/2021/
may/statement-ambassador-katherine-tai-covid-19-trips-waiver
[hereinafter Statement
from Ambassador Tai.]
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submitted to the General Council. 80

TRIPS Council

The European Union proposed an alternative
81
plan to the proposed TRIPS waiver.

European Union

6/8/21;

The TRIPS Council decided that text-based

TRIPS Council

6/9/21

negotiations
forthcoming.82

6/24/21

The TRIPS Council met to discuss increased

TRIPS Council

access to vaccines, as proposed by the

(informal meeting)

6/4/21

should

take

place

European Union. 83
7/1/21

Grace period for LDC implementation of
TRIPS is set to expire. When the period
expires, LDCs must adhere to TRIPS
provisions, with an exception for drug
patents. LDCs do not have to adhere to
TRIPS for drug patents until January 2033.84

TRIPS Agreement

7/21/21;
7/22/21

The General Council met to negotiate the
proposal"5 and adopt a report on the status of
the negotiations.86

WTO
Council

General

Week of

The General Council reconvened following

WTO

General

9/6/21

summer break. 87

Council

11/26/21

The General Council indefinitely postponed
upcoming conference meeting because of

WTO
Council

omicron variant. 88

General

80.
81.
82.
83.
84.

WTO Waiver, May 25, 2021, supra note 41.
Hu, supra note 53.
Green, supra note 48.
Hu, supra note 53.
World Trade Organization, WTO Members Agree to Extend Drug Patent
Exemption for Poorest Members, Nov. 6, 2015,

https://www.wto.org/english/news_e/news
85.
86.

Green, supra note 48.
Baschuk, supra note 1.

87.
88.

Id.

15e/trip_06nov15_e.htm.

World Trade Organization, General Council Decides to Postpone MC12

Indefinitely, supra note 72.
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Countries may "officially" or "formally" support the waiver by signing
the proposal before the WTO, which sixty countries had done for the
original proposal by late April 2021." Countries might also show public
support for or opposition to the waiver or parts of the waiver. According
to the WTO, there are several countries who support some type of waiver
but take issue with the ambiguity of the South Africa and India waiver
proposal or some other facet of that proposal.9 0
The revised waiver to waive TRIPS amidst COVID-19 provides some
new clarity to the proposed terms. The working version of the document
as of now, IP/C/W/669/Rev. 1, clarifies that the waiver should continue
for a minimum of three years after the General Council decides to
implement the waiver.9 1 For the years following, the General Council is
to review the circumstances relevant to the waiver and determine whether:
(1) those circumstances no longer exist and (2) the waiver should be
terminated.9 2 In addition, the General Council, within one year of granting
the proposal, must review the waiver and continue to do so annually in
accordance with paragraph 4 of Article IX of the Marrakesh Agreement.9 3
Article IX, paragraph 4 states that waivers granted: (1) for more than one
year and (2) under exceptional circumstances must be reviewed by the
overseeing body within one year of their implementation and annually
until they no longer apply.9 4 Upon such review, the overseeing body must
ascertain whether the exceptional circumstances allowing the waiver still
exist, and whether the terms and conditions of the waiver have been met.
Finally, Marrakesh Agreement, Article IX, paragraph 4 states that the
overseeing body, upon annual review of the waiver, has the power to
extend, modify, or terminate it.9

89.

World Trade Organization, TRIPS Council to Continue to Discuss Temporary

IP Waiver, RevisedProposalExpected in May, supranote 78.

90.
D. Ravi Kanth, Developed Countries Continue to Block TRIPS Waiver
Proposal,THIRD WORLD NETWORK, Nov. 23, 2020,
https://www.twn.my/title2/intellectual_property/info. service/2020/ip20 1108.htm.
91.
WTO Waiver, May 25, 2021, supra note 41, at 3.

92.
93.
94.

Id.
Id.
Marrakesh Agreement Establishing the WTO art. 9 ¶4, Apr. 15, 1994, 1867

U.N.T.S. 154.

95.

Id.

Stumbling Over TRIPS

2022]

267

The proposed waiver has, in both drafts, outlined several TRIPS
requirements to be abandoned considering the COVID-19 pandemic. The
first version of the proposal urges the waiver of TRIPS protections
(contained in Sections 1, 4, 5, and 7 of Part II) for essential medical
products that create barriers to access, such as patents, industrial designs,
copyrights, and protection of undisclosed information. 96 The first version
also cited Article 31bis requirements on compulsory licenses as
problematic for countries with poor manufacturing capacity, but did not
explicitly or unambiguously request the General Council to waive the
requirements of TRIPS Article 31 bis.9" The revision narrows and clarifies
that such waiver shall apply to Sections 1, 4, 5, and 7 of Part II of TRIPS
for "health products and technologies including diagnostics, therapeutics,
vaccines, medical devices, personal protective equipment, their materials
or components, and their methods and means of manufacture for the
prevention, treatment or containment of COVID-19."98 The revision
abandons any mention of Article 31bis, compulsory licenses.99
Due to the change in the proposal, Article 31bis on compulsory licenses
is no longer being discussed as a waived provision of TRIPS under this
schema for curbing COVID. Article 31bis waives the domestic use
requirement for compulsory licensing, which previously required products
to be used mostly in the domestic market in order to qualify for a
compulsory license under TRIPS.100 Under the waiver, a country can issue
a compulsory license that is primarily for export to another country;
however, the other Article 31 requirements still require a lot of heavy
lifting for both the importing and exporting country, and compulsory
licenses are somewhat difficult to procure even with the Article 31bis
waiver in place.10 1 South Africa and India initially brought up this issue in
96.

WTO Waiver, Oct. 2, 2020, supra note 73, at 1.

97.

Id, at 2.

98.
99.

WTO Waiver, May 25, 2021, supra note 41, at 1.
WTO Waiver, May 25, 2021, supra note 41; see also Part II-

Standards

ConcerningtheAvailability, Scope and Use oflntellectualPropertyRights,WORLD TRADE
https://www.wto.org/english/docse/legale/27-trips_04_e.htm (visited Oct. 20,
2021). Under TRIPS, Part II, Section 1 discusses copyrights, Section 4 discusses industrial
designs, Section 5 discusses patents, and Section 7 discusses protection of undisclosed
information. Id
100. CYNTHIA M. Ho, ComplicatedCompulsoryLicenses: The Waiver/Article3lbis
'Solution', in ACCESS TO MEDICINE IN THE GLOBAL ECONOMY 196, 197 (2011); Kumar,
supra note 3.
ORG.,

101.

Id. at 198.
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the proposal for the TRIPS waiver, but it has been abandoned and is not
even mentioned in the revised version. 102 This suggests that if the waiver
of TRIPS requirements for certain types of intellectual property during
COVID-19 goes through, a revision or exemption of requirements for
compulsory licenses will have to come from another proposal or source.
Certain TRIPS exemptions and provisions related to pharmaceutical
products already exist outside of the proposed exemptions. 103 For example,
governments can refuse to grant patents for "diagnostic, therapeutic, and
surgical methods" for treating humans and animals. 10 4 Several additional
waivers of compulsory licensing requirements also exist under Article
31bis and binding WTO decisions, and they apply to pharmaceutical
products. 105 Despite their existence, about 50 of the WTO members do not
use or very seldom use these TRIPS provisions and WTO-approved
waivers for pharmaceutical products. 106
There are a variety of procedural issues facing the proposed waiver.
The procedural aspects most pertinent to the TRIPS waiver are the
procedures of the WTO and the TRIPS Council, the procedural history of
the WTO and similar entities regarding emergency use and prior waivers
or proposals, and the possible future consequences of allowing such
waivers during emergencies, like the pandemic. The WTO and its
subsidiary TRIPS Council have not done anything substantive with the
waiver the original waiver was proposed in October 2020, but the WTO
has not made a decision that binds the members. The WTO is a rulesbased, member-driven organization that makes most of its decisions based
on consensus, which is established when no member state formally objects
to a decision made by the General Council. 107 Formal objection is not well-

102.

WTO Waiver, May 25, 2021, supra note 41.

103. Fact Sheet: TRIPS and Pharmaceutical Patents: Obligations and Exceptions,
WORLD TRADE ORG. (Sept. 2006),
https://www.wto.org/english/tratop_e/tripse/factsheet_pharm02_e.htm
Pharmaceutical Patents].

104.

[hereinafter

Part Il-StandardsConcerning the Availability, Scope and Use of Intellectual

Property Rights, WORLD TRADE ORG., https://www.wto.org/english/docse/legale/27trips 04 e.htm (visited Oct. 20, 2021) (referring to Art. 27(3)(a)).
105.
Pharmaceutical Patents, supra note 103.

106.

Id.

107.
Georgetown Law Library, International Trade Law Research Guide: WTO
Organizational Structure & Decision Making,
https://guides.ll.georgetown.edu/c.php?g=363556&p=4154931
(last updated Dec. 2,

2021).
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defined, and consensus is generally inferred where there is no writing or
other suggestion that a member state is vehemently opposed to a
decision." Consensus requires all 164 member states to agree on a
proposal.109 If a period of time undefined passes and the members fail
to reach consensus, the General Council will vote on the proposal, and a
two thirds vote is required for the proposal to pass." 0
On May 25, 2021, the TRIPS Council recommended, following several
prior recommendations, that the General Council should formally discuss
and rule on the revised proposal for the TRIPS waiver." The proposed
waiver was the only working document within the TRIPS Council docket
as of June 2021, and the General Council had planned to discuss the TRIPS
waiver as a formal matter of business for its next meeting.1 1 2 Generally,

issues that are outside of the mandatory agenda for the TRIPS Council are
discussed ad hoc, which leaves room for the WTO to ignore, postpone, or
change agendas regarding proposals such as the TRIPS waiver and the
revision. 113

The TRIPS Council has previously made rulings via the member states
that are enforced by the WTO and binding on the member states. Most
notably, in 2015, the TRIPS Council, without opposition from member
states, waived TRIPS requirements for least-developed countries (LDCs)
for pharmaceutical products. 1 1 4 The exemption for LDCs already was in
place, but the 2015 decision by the TRIPS Council extended that
exemption to January 2033
because of this extension of the exemption
period, LDC member countries are exempt from TRIPS requirements for
pharmaceutical products at present." The implication of the extension of
the LDC exemption period is twofold: first, it shows that the TRIPS
Council has made unanimous decisions that were accepted as binding on
108.
109.

Id.

Id.

110.
World
Trade
Organization,
Whose
WTO
Is
It Anyway?,
https://www.wto.org/english/thewto_e/whatis_e/tif_e/orgl_e.htm (visited Jan. 7, 2022).
111.
WTO Waiver, May 21, 2021, supra note 41.

112.
113.

Id.

World Trade Organization, Module XT
Current TRIPS Issues,
https://www.wto.org/english/tratope/trips_e/tadocs_e/modules11_e.pdf (visited Jan. 7,

2022).
114.
World Trade Organization, WTO Members Agree to Extend Drug Patent
Exemptionfor PoorestMembers, Nov. 6, 2015,
https://www.wto.org/english/news_e/newsl5_e/trip_06nov15_e.htm.

115.

Id.
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WTO members, and second that LDCs are not bound by TRIPS
requirements for pharmaceutical products, which applies to the question
about COVID vaccines. At present, there are thirty-five LDC members of
the WTO. 116
IV. THE EVOLUTION OF THE U.S. POSITION ON THE WAIVER

The U.S. and some European countries have been staunch opponents
of the waiver.1 1 7 The U.S. only changed its critical position in May 2021,
when the Biden administration backed the waiver and proclaimed its
public support for the waiver of certain IP requirements under TRIPS." 8
According to Reuters, the Biden administration changed the U.S. position
on the waiver following pressure from democratic lawmakers in the U.S.
and more than one hundred countries who are in support of the waiver.11 9
The Biden-Harris administration issued a statement supporting the TRIPS
waiver to international intellectual property rights,12" an about-face from
the prior administration's staunch opposition to any effort to support
global access and distribution. U.S. Trade Representative Katherine Tai
made the statement on May 6, 2021, announcing that the U.S. had changed
its stance and was now in support of the proposed IP waiver for COVID
vaccines.121 The statement issued by Tai carefully limited support of the
waiver to vaccines, a narrower segment of medical products and

116.

World

Trade

Organization,

Least-Developed

Countries,

https://www.wto.org/english/thewtoe/whatisc/tif _e/org7_e.htm#:~:text-Eighto20more
%20leastdeveloped%20countries%2 Oare%20negotiating%20to%20join,no%20WTO%20definitio
ns%20of%20%E2%80%9CdevelopedE2%80%9 D%20 or % 2 0%E2%80%9Cdeveloping
0 countries (visited Jan. 18, 2022).

%E2%80%29D%2

117.
Sidhant Sibal, WTO to Take Up India-SAfrica Proposalfor Waiver on iP
Rights for COVID Vaccines on Feb 23, WION, Feb. 5, 2021,
https://www.wionews.com/india-news/wto-to-take-up-india-safrica-proposal-for-waiveron-ip-rights-for-covid-vaccines-on-feb-23-361554.
118.
Shalal et al., U.S. Reverses Stance, Backs Giving Poorer CountriesAccess to
COVD Vaccine Patents, REUTERS, May 5, 2021,
https://www.reuters.com/business/healthcare-pharmaceuticals/biden-says-plans-back-

wto-waiver-vaccines-2021-05-05/.
119. Id.
120.
121.

Statement from Ambassador Tai, supranote 79: Shalal et al, supranote 118.
Statement from Ambassador Tai, supranote 79.
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information than contemplated in the most recent version of the petition
for waiver.

122

The current proposed waiver at the WTO seeks to waive TRIPS
requirements for "health products and technologies including diagnostics,
therapeutics, vaccines, medical devices, personal protective equipment,
their materials or components, and their methods and means of
manufacture for the prevention, treatment, or containment of COVID19.123 The U.S. did not sign the original or revised proposal, but instead
publicly expressed its support through the Trade Representative's
statement. 12 4 Representative Tai stated in the "official" statement from the
U.S., "The [Biden] Administration believes strongly in intellectual
property protections, but in service of ending this pandemic, supports the
waiver of those protections for COVID-19 vaccines."1 2 Representative
Tai went further to say,
"The Administration's aim is to get as many safe and effective vaccines
to as many people as fast as possible. As our vaccine supply for the
American people is secured, the Administration will continue to ramp up
its efforts - working with the private sector and all possible partners - to
expand vaccine manufacturing and distribution. It will also work to
increase the raw materials needed to produce those vaccines. 1 26

Representative Tai's choice wording that the U.S. supports the
proposed waiver of TRIPS requirements, under the first proposal at the
WTO by South Africa and India, applies to vaccines, but there is not an
explicit indication that: (1) the U.S. fully supports the waiver for the
proposed items in the first version of the proposal; (2) the U.S. fully
supports the waiver for the proposed items in the revised version of the
proposal: or (3) the U.S. only supports either version of the waiver with
respect to vaccines. There is, however, some indication that the U.S. Trade
Representative's phrasing indeed only applies U.S. support to waiver of
TRIPS requirements despite COVID-19 for vaccines, because some

122.

Id.

123.
124.
125.

WTO Waiver, May 25, 2021, supra note 41.
Statement from Ambassador Tai, supranote 79.

126.

Id.

Id.
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stakeholders have urged the Biden Administration to also consider the
waiver for other COVID-relevant items.127
In May 2021, Senator Warren expressly asked Representative Tai
whether the U.S. supports the waiver for vaccines only, or if it also applies
to diagnostics, therapeutics, and PPE.1 2 Representative Tai responded that
the U.S. will focus on vaccines, in an effort to answer the time-sensitive
vaccine crisis.1 2 9 When asked again, Representative Tai reiterated that
vaccines are the priority and that the U.S. supports the waiver of TRIPS
for vaccines and raw materials, but that the U.S. recognizes the need for
diagnostic testing and PPE.13 o It remains unclear whether Representative
Tai is suggesting that the U.S. supports the waiver of TRIPS requirements
for PPE and diagnostic testing, even after the exchange with Senator
Warren.
Leading up to and before this shift in support of the waiver, the Trump
administration supported the general trend of the U.S. upholding strong
intellectual property rights. The U.S. has historically maintained very
strong IP rights, with the annual number of issued patents having
quintupled since several pieces of important legislation in the 1980s.13 1 In
2021, the U.S. was ranked second in global patent protection, for the third
year in a row.13 2 The U.S. is the global leader in copyright and trademark
protections, amidst a general global trend toward stronger IP rights.1 33
During the Trump administration, the U.S. Patent Office was headed by
those in strong support of strong intellectual property rights, who
consequently also opposed the proposal by South Africa and India.1 3 4 In
contrast, however, the Biden administration has made some indications

127.
Green, supra note 48.
128.
Press Release, Elizabeth Warren, Warren to Tai at Hearing: Our Trade
Negotiations Must Put Patients Over Big Pharma Profits, May 12, 2021,
https://www.warren. senate.gov/newsroom/press-releases/warren-to-tai-at-hearing-ourtrade-negotiations-must-put-patients-over-big-pharma-profits.
129.
Id.

130.

Id.

131.
Brink Lindsey, Why Intellectual Property and Pandemics Don't Mix,
BROOKINGS, June 3, 2021, https://www.brookings.edu/blog/up-front/2021/06/03/whyintellectual-property-and-pandemics-dont-mix/.
132.
Tiffany Hu, supranote 30.

133.
134.

Id.

Ian Lopez, Biden Vaccine IP Waiver Stance Offers Clue on PatentOfficePick,

BLOOMBERG LAw, May 17, 2021, https://news.bloomberglaw.com/coronavirus/bidenvaccine-ip-waiver-stance- offers-clue-on-patent-office-pick.
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that the Patent Office will spearhead support of strong intellectual property
rights and simultaneously uphold the new and current U.S. stance in
support of a TRIPS waiver.135
Early in the Biden administration, Democratic lawmakers urged the
President to support the IP waiver. Around March 2021, pressure from
developing countries and support from progressive lawmakers pushed the
White House to consider the IP waiver. 136 Senator Pelosi and several
Democratic colleagues issued a letter to urge the Biden administration to
further study the waiver issue. 137
U.S. Representatives DeLauro,
Schakowsky, Blumenauer, Dogget, Espaillat, and Levin urged President
Biden to support a temporary TRIPS waiver in March 2021.138 They
argued that the U.S. had lost its position and status as a global health leader
and that COVID is a crisis requiring global collaboration. 139 More than
sixty U.S. Representatives joined to urge President Biden to support the
South Africa-India proposal at the WTO. 14 0 In early April 2021, Senators
Baldwin, Blumenthal, Brown, Markley, Merkley, Murphy, Sanders, Van
Hollen, Warnock, and Warren wrote a letter to President Biden urging him
to support the IP waiver for COVID vaccines.14 1 Lawmakers cited damage
done during former President Trump's tenure as the president.14 2 A Data
for Progress and Progressive International poll showed that sixty percent
of U.S. voters supported the waiver, including fifty percent of registered
Republicans.1 4 3 Democratic lawmakers were largely supportive of a
temporary IP waiver, especially following strong lobbies from Senators
135.

See Id.

136. Tausche et al., White House Weighs Temporarily Lifting IntellectualProperty
Shield on COVID-19 Vaccines, CNBC, Mar. 26, 2021,
https://www.cnbc.com/2021/03/26/covid-vaccine-updates-white-house-mulls-liffingintellectual-property-shield.html.

137.

Id.

138.
Press Release, DeLauro, Schakowsky, Blumenauer, Doggett, Espaillat, Urge
Biden Administration to Support COVID-19 Waiver to Boost Global Distribution of
Vaccines and Therapeutics, Mar. 17, 2021, https://delauro.house.gov/media-center/pressreleases/delauro-schakowsky-blumenauer-doggett- espaillat-levin-urge-biden.

139.

Id.

140.

Id.
Colleagues UrgeBidentoApprove VaccinePatentWaiverto BoostProduction
and EndPandemic,Apr. 16, 2021,
https://www.warren.senate.gov/newsroom/press-releases/ warren- colleagues-urge-bidento-approve-vaccine-patent-waiver-to-boost-production-and-end-pandemic.
142. Id.

141.

143.

Id.
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1

Warren and Biden. " At the time the U.S. announced its support for the
waiver, more than one hundred House Democrats supported the TRIPS
waiver for vaccines and treatments.14 5

Despite a general trend in progressive U.S. legislators supporting the
waiver, a number of Democrats refused to back the COVID vaccine patent
waiver, even before President Biden expressed U.S. support via
Ambassador Tai.14 6 Of the top twenty-five members of the House who
received money from the pharmaceutical industry, nine are Democrats.1 4 7
None of those Democrats have signed the letter from other House
members urging the President to support the waiver.148 Democratic
opponents of the waiver cite harm to the global competitiveness of the
U.S., the inability of the waiver to solve a shortage issue, and
manufacturing capacity issues that would stunt the effectiveness of the
waiver.14

The general U.S. trend toward strong protection of intellectual property
rights is evidenced by pushback to the Biden administration's change of
position regarding the TRIPS waiver proposal.
PhRMA and
pharmaceutical companies strongly opposed the U.S. decision to reverse
its prior stance on the TRIPS waiver.
Following U.S. Trade
Representative Katherine Tai's statement that the U.S. supports the
proposal for the waiver of TRIPS requirements during the pandemic, the
pharmaceutical industry voiced collective frustration." 0 Moderna and
several other pharma superpowers argue that there is insufficient
manufacturing capacity to supply the rapid or even near-term deployment
of widespread mRNA vaccines, even if there were to be a patent or IP

144.
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"

waiver. 15 1 U.S. industry and trade organizations opposed to the waiver
claim that it is broad and sweeping, vague, and undermines wellestablished IP rights.15 2 Some pharmaceutical companies purport that the
waiver undermines pharmaceutical investment and intellectual property
assets worth tens of billions of U.S. dollars.1 " The Wall Street Journal
reflected these concerns, while also expressing concern that the U.S. has
given up its stronghold on innovation via intellectual property, especially
in the patent space. 1 4 Pfizer, Moderna, Johnson & Johnson, and the U.S.
Chamber of Commerce have consistently opposed democratic lobbies to
support the waiver, including for vaccines, personal protective equipment,
diagnostics, and treatments for COVID-19.155
Both up to and following Ambassador Tai's announcement, a handful
of U.S. lawmakers and activist groups have pushed the President to expand
U.S. support of the waiver beyond application solely to vaccines. 15 6 These
groups seek to expand U.S. support not only to include vaccines, but also
critical treatments and diagnostics. 157 In addition, activists have urged Dr.
Anthony Fauci and other federal officials to use a government-owned
patent to make Moderna's COVID vaccine more widely available.1
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Moderna has contracted with a manufacturer to produce the drug
substance for the vaccine, but has failed to provide the technology to
developing countries. 159 In a letter to Secretary Becerra and others on the
use of the patent, proponents suggested that the agreement would: (1)
empower the U.S. to authorize production of the mRNA strand necessary
for the vaccine, (2) require technology sharing with the WHO to expedite
global production, and (3) include requirements for accessible pricing

universally. 160
Until the switch in the U.S. position, the U.S., E.U., Australia, Brazil,
Canada, Japan, Norway, Singapore, Switzerland, Taiwan, and the U.K.
had all opposed the joint proposal for the TRIPS waiver.16 1 China and
Russia both support the waiver.1 6 2 Germany has consistently opposed the
waiver.1 6 3
Switzerland, South Korea, and Japan are expected to
continually oppose the waiver due to the influence of wealthy
pharmaceutical companies. 164 Some of the waiver's opponents say that the
waiver will not solve vaccine nationalism, hoarding of supplies, and poor
sharing of COVID vaccines. 165 Many wealthy countries were adverse to
the IP waiver before the U.S. expressed its position in support- once the
U.S. expressed support, a number of developing countries expressed
support for the revised proposal. 166 Supporters claim that the waiver will
boost vaccine production, that it is more desirable and efficient than
compulsory licenses, and that public health is to be prioritized over
profits. 167 Supporters look to a bottlenecking effect, claiming that
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intellectual property protections on patents, copyrights, trade secrets, and
industrial designs greatly hinder production of critical medical products. 168
Opponents say that the waiver is a red herring, that it will stunt innovation,
and that there is insufficient manufacturing capacity even with the waiver
in place. 169
V. ALTERNATIVE MODELS FOR ACCESS AND DISTRIBUTION

There is intense disagreement on whether the waiver is an effective and
appropriate way to address the vaccine shortage. The director-general of
the WTO, Ngozi Okonjo-Iwela, made a statement in late May that the
waiver is insufficient as a method to expedite the provision of vaccines in
countries that are behind and many legal commentators agree. 170 There is
no evidence, as argued by those agreeing with Okonjo-Iweala, that there
is an international mechanism or system whereby IP laws protected and
required by TRIPS impede the "development, production, or distribution
of vaccines and treatments for COVID."171 They further argue that generic
companies who already have begun production have not cited IP as the
issue that needs to be solved at the global scale for faster production and
increased volume of COVID vaccines and treatments. 172
There is an additional group of countries and companies that support
the waiver in general but have issues with the specific proposal and
revision put forth to the WTO. 17 The ambiguity in the first proposal and
the unresolved lack of clarity in the revision leaves some entities unclear
on whether the specific method of the waiver should be supported or not.17 4
One existing obstacle to the waiver of TRIPS requirements, despite the
pandemic, is a lack of consensus on whether compulsory licenses will
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secrets. 175 In the past,

compulsory licenses have not required the divulsion of trade secrets, so it
is unclear where the suspicion comes from beyond speculation. 176 Law360
goes further to say that critics of the waiver claim that it will impede
speedy and equitable vaccine distribution and weaken IP rights globally. 177
The waiver was blocked by the EU., U.K., Switzerland, Japan, and some
other countries. Despite heavy lobbying of Congress by pharmaceutical
companies to deny the waiver, the U.S. has expressed support, though has
also been criticized for a lack of movement with that support or follow up
on questions of scope of that support.178 At present, Medecins Sans
Frontieres (Doctors Without Borders) has a map of countries that support
or oppose the waiver. 179
One controversial issue regarding the waiver of certain TRIPS
provisions is whether it would require disclosure of certain information
that is considered trade secrets by big pharma companies. 180 The TRIPS
provision of concern is Part II, Section 7 on protection of undisclosed
information. Section 7, Article 39, paragraph 1 states that members shall
protect against unfair competition in accordance with Article 10bis of the
Paris Convention for the Protection of Industrial Property. 181 Article 39,
paragraph 2 outlines that natural and legal persons have the possibility to
prevent others from acquiring information that is: (1) secret, (2) has
commercial value because it is secret, and (3) has been subject to
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reasonable measures to be kept a secret.i 2 Finally, Article 39, paragraph
3 states that members, as a condition of approving marketing of
pharmaceutical products, should protect clinical data against unfair
commercial use.183 Article 39, paragraph 3 provides that members should
protect clinical data against disclosure, except where necessary to protect
the public or steps are taken to ensure that the data are protected against
unfair commercial use. 184

The TRIPS provisions regarding undisclosed information are
somewhat ambiguous. The ambiguity in the treaty leaves pharmaceutical
companies' ample opportunity to argue that trade secrets are protected and
defined in Article 39, and that disclosure of trade secrets via the proposed
waiver further interferes with companies' monopolistic IP rights and
threatens their profits.
An alternative approach based on international organization and
cooperation has also been proffered: a joint effort by the WTO and WHO,
wherein public health issues are governed with special attention to TRIPS
and the Doha Declaration. 185 The proposed effort would include a
committee for emergency preparedness and response, a specific dispute
settlement mechanism that is separate from the general quasi-judicial
method of the WTO, incentives for members to report public health issues,
and permissions for member states to take actions, otherwise forbidden,
during disease outbreaks with high risk and virulence with clear, unilateral
trade restrictions that would cause a large, unjustified burden on a member
country. 186
The WHO and WTO Secretariat have offered some opinions on how to
deal with public health crises and balance the interests of the public with
the interests of intellectual property owners. The WHO and WTO
Secretariat have suggested solutions and measures outside of intellectual
property, including: (1) price and reimbursement controls; (2) tiered or
equity pricing; (3) bilateral negotiation of price discounts between
companies and governments, use of bulk purchasing power, voluntary
licensing, and compulsory licensing; (4) voluntary price cuts that are
182.
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accessible to all, not only some, countries; and (5) donation of drugs or
treatments during global public health emergencies. 187

A shared opinion by some proponents on both sides of the aisle of the
TRIPS waiver debate is that waiving patents, on its own, is not enough to
end the pandemic. 1 Some have suggested that the waiver of IP
protections during COVID is necessary, but it is not sufficient to solve the
pandemic. 189 A primary logistical barrier, even with the imposition of a
waiver, is the inability of manufacturers to produce and distribute
vaccines. 190 In addition, pharma companies are reluctant or averse to
sharing their technological experience and knowledge, and governments
back those companies by refusing to compel that transfer. 191 Big
corporations report that mRNA vaccines are especially difficult to
distribute and manufacture on a large scale, because they are complex and
relatively new
the same argument is made about adenovirus vaccines,
but to a lesser extent. 192 Pharmaceutical companies also hold on to their
technology and knowledge, because they consider them indispensable
trade secrets.193
Those in support of the waiver plus additional efforts claim that
windfall profits have already gone to pharma companies, and significant
public funding is available to support institutions that otherwise would not
have been able to meet the current demand for production and distribution
of vaccines. 19 4 One Indian company already produces a large amount of
the AstraZeneca vaccine for Europe, and supporters of technology transfer
plus the TRIPS waiver argue that there is no reason to believe that this
particular Indian company and others do not have the ability to meet the
manufacturing and production needs once the technology becomes
available. 195 Supporters further argue that the U.S. is in a position where
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the government can: (1) supply multinationals with ample financial
incentives to build capacity to vaccine production and (2) apply pressure
on companies by threatening to sequester existing patents if the company
fails to adhere to compulsory technology transfers. 196
The International Federation of Pharmaceutical Manufacturers and
Associations (IFPMA) joins many opponents of the TRIPS waiver, stating
that it is not a worthy solution, either on its own or in conjunction with
another. 9 7 IFPMA suggests that, instead of a waiver, trade barriers,
bottlenecks in supply chains, and shortages of raw materials must be
eliminated to fix the production and distribution challenges amidst the
pandemic. 198 The IFPMA Chief cited 275 ongoing manufacturing deals,
including technology transfer, which helped the industry grow from zero
to one billion COVID vaccine doses, looking toward ten billion doses by
the end of 2021.199 Some pharma industry actors oppose technology
transfer, because they are unsure about the safety and quality standards of
the recipient manufacturers.200 Moderna, for example, has argued that
technology transfer will take away raw materials from the companies that
have the capacity to meet the global production and distribution demand
and erroneously give them to those that do not have that capacity.201
However, firms in Bangladesh, Canada, South Korea, and Pakistan have
expressed their interest and ability to make vaccines once the waiver is
approved and implemented, which suggests that there is not a uniform
issue in manufacturing problems across the nations that are relying on the
possibility of an IP waiver.oz
A final consideration regarding the issues with the proposed waiver of
TRIPS requirements related to COVID is whether a cooperative global
effort or a national effort is more effective. A late 2020 projection used a
public health epidemiology model to predict whether, for a vaccine with
sixty-five to eighty percent efficacy, the overall effect of global
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2 03

cooperation versus non-cooperation would be best.
Using the Global
Epidemic and Mobility Model (GLEAM), the authors found that the
cooperative model averted the most COVID-related deaths for a
hypothetical vaccine with sixty-five percent efficacy and another
hypothetical vaccine with eighty percent efficacy. 2 04 The study does not
provide details on how the vaccines would be acquired, manufactured, or
allocated, but provides insight that, epidemiologically,
a global
collaborative effort to eradicate COVID-19 via vaccination is more likely
than isolated efforts to succeed.2 05
VI. CONCLUSION

The implications of the controversy surrounding the petition for waiver
of IP rights under TRIPS will be felt for decades. The limitations of
procedures without meaningful resolution mechanisms, reluctance of
international bodies to make determinative decisions, and intense
disagreements over the purpose of IP and the importance of global health
and safety will be one resounding legacy of the COVID-19 pandemic. The
process for reaching consensus or taking votes on passing proposals is
undefined. Many countries still express at least partial opposition to the
waiver, further delaying consensus or a situation where a vote may bring
the proposal to action. As of November 2021, there have not been any
major updates in the progress of the proposed waiver from the WTO given
the requirement of consensus from the General Council and the
controversy surrounding the scope of the waiver itself.
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